MDMA alters emotional processing and facilitates positive social interaction
This study (n=36) assessed the effects MDMA (52.5-105 mg/70kg) has on perceptions of and responses to emotional expressions and its effects on social interaction. MDMA slowed the perception of angry expressions, increased psychophysiological responses to happy expressions, and increased positive word use and perceptions of partner empathy and regard in a social interaction.
Abstract
Background
±3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) produces “prosocial” effects, such as feelings of empathy and closeness, thought to be important to its abuse and its value in psychotherapy. However, it is not fully understood how MDMA alters basic emotional processes to produce these effects or whether it produces corresponding changes in social behaviour. Here, we examined how MDMA affects perceptions of and responses to emotional expressions and tested its effects on behaviour during a social interaction. We also examined whether MDMA’s prosocial effects are related to a measure of abuse liability.
Methods
Over three sessions, 36 healthy volunteers with previous ecstasy use received MDMA (0.75, 1.5 mg/kg) and a placebo under double-blind conditions. We measured (i) mood and cardiovascular effects, (ii) perception of and psychophysiological responses to emotional expressions, (iii) use of positive and negative words in a social interaction, and (iv) perceptions of an interaction partner. We then tested whether these effects predicted the desire to take the drug again.
Results
MDMA slowed perception of angry expressions, increased psychophysiological responses to happy expressions, and increased positive word use and perceptions of partner empathy and regard in a social interaction. These effects were not strongly related to a desire to take the drug again.
Conclusions
MDMA alters basic emotional processes by slowing the identification of negative emotions and increasing responses to positive emotions in others. Further, it positively affects behaviour and perceptions during actual social interaction. These effects may contribute to the efficacy of MDMA in psychotherapy but appear less closely related to its abuse potential.
Research Summary of 'MDMA alters emotional processing and facilitates positive social interaction'
Introduction
MDMA (3,4-methylenedioxymethamphetamine, “ecstasy”) produces characteristic stimulant effects together with distinctive ‘‘prosocial’’ effects such as increased feelings of closeness, empathy and desire to socialise. Earlier research has shown that MDMA can reduce perception of negative facial expressions and reduce amygdala responses to anger, and some studies suggest it may enhance recognition or neural responses to positive expressions. However, previous work has focused mainly on perception of static stimuli, leaving uncertain whether MDMA also alters emotional responses after perception and whether these effects translate into measurable changes in real social behaviour. Wardle and colleagues set out to characterise how MDMA affects both perception of and psychophysiological responses to emotional facial expressions using dynamic, full‑colour video stimuli, and to test whether it changes behaviour and subjective perceptions during a controlled face‑to‑face social interaction. They also probed, on a preliminary basis, whether any prosocial effects related to self‑reported desire to take the drug again as an index of abuse liability.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Author
- APA Citation
Wardle, M. C., & de Wit, H. (2014). MDMA alters emotional processing and facilitates positive social interaction. Psychopharmacology, 231(21), 4219-4229. https://doi.org/10.1007/s00213-014-3570-x
References (7)
Papers cited by this study that are also in Blossom
Bedi, G., Hyman, D., De Wit, H. · Biological Psychiatry (2010)
Bouso, J. C., Doblin, R., Farré, M. et al. · Journal of Psychoactive Drugs (2008)
Frye, C. G., Wardle, M. C., Norman, G. J. et al. · Pharmacology Biochemistry and Behavior (2014)
´dric, C., Hysek, M., Schmid, Y. et al. · Social Cognitive and Affective Neuroscience (2013)
Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2009)
Kirkpatrick, M. G., Lee, R., Wardle, M. C. et al. · Neuropsychopharmacology (2014)
Liechti, M. E., Gamma, A., Vollenweider, F. X. · Psychopharmacology (2001)
Cited By (31)
Papers in Blossom that reference this study
Goldy, S. P., Sepeda, N. D., Hilbert, S. N. et al. · Psychiatry Research (2026)
Martinez, R. L., Radošić, N., Molla, H. et al. · Journal of Psychopharmacology (2025)
Agin-Liebes, G. I., Zeifman, R. J., Mitchell, J. · European Journal of Psychotraumatology (2025)
Zhang, X., Hack, L. M., Bertrand, C. et al. · JAMA Network Open (2025)
Zacher, A., Zimmermann, J., Cole, D. M. et al. · European Neuropsychopharmacology (2024)
Haggarty, C. J., Bershad, A. K., Kumar, M. K. et al. · European Journal of Neurology (2024)
Bershad, A. K., Hsu, D. T., De Wit, H. · Journal of Psychopharmacology (2024)
Zeifman, R. J., Kettner, H., Ross, S. et al. · European Journal of Psychotraumatology (2024)
Molla, H. M., Lee, R., Lyubomirsky, S. et al. · Scientific Reports (2023)
Sarmanlu, M., Kuypers, K. P. C., Vizeli, P. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2023)
Show all 31 papersShow fewer
Ponomarenko, P., Seragnoli, F., Calder, A. et al. · Journal of Psychopharmacology (2023)
Brewerton, T. D., Wang, J. B., Lafrance, A. et al. · Journal of Psychiatric Research (2022)
Regan, A., Margolis, S., De Wit, H. et al. · PLOS ONE (2021)
Chaliha, D., Mamo, J. C., Albrecht, M. et al. · Current Neuropharmacology (2021)
de Wit, H., Bershad, A. K., Grob, C. S. · Journal of Psychopharmacology (2021)
Varker, T., Watson, L., Gibson, K. et al. · Journal of Psychoactive Drugs (2020)
Reiff, C. M., Richman, E. E., Nemeroff, C. B. et al. · American Journal of Psychiatry (2020)
Preller, K. H., Vollenweider, F. X. · Frontiers in Psychiatry (2019)
Bershad, A. K., Mayo, L. M., Van Hedger, K. et al. · Neuropsychopharmacology (2019)
Carlyle, M., Stevens, T., Fawaz, L. et al. · Journal of Psychopharmacology (2019)
Jungaberle, H., Thal, S., Zeuch, A. et al. · Neuropharmacology (2018)
Vizeli, P., Liechti, M. E. · PLOS ONE (2018)
Bershad, A. K., Miller, M. A., De Wit, H. · Psychopharmacology (2017)
Bershad, A. K., Miller, M. A., Baggot, M. J. et al. · Journal of Psychopharmacology (2016)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
Sessa, B. · Neuroscience Letters (2016)
Dolder, P. C., Schmid, Y., Müller, F. et al. · Neuropsychopharmacology (2016)
Bershad, A. K., Weafer, J. J., Kirkpatrick, M. G. et al. · Social Neuroscience (2016)
Baggot, M. J., Coyle, J. R., Siegrist, J. D. et al. · Journal of Psychopharmacology (2015)
Kirkpatrick, M. G., Delton, A. W., de Wit, H. et al. · Journal of Psychopharmacology (2015)
Sessa, B., Nutt, D. J. · British Journal of Psychiatry (2015)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.